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Percutaneous coronary interventionThe study aim was to determine the predictive value of interleukin (IL)-33, a recently described member
of the IL-1 family of cytokines, for the development of in-stent restenosis (ISR). IL-33 serum levels were
measured in 387 consecutive patients undergoing percutaneous coronary intervention (PCI) of whom
193 had stable angina, 93 non-ST elevation myocardial infarction (NSTEMI), and 101 ST-elevation MI
(STEMI), respectively. Blood was taken directly before and 24 h after stent implantation. The presence
of ISR was initially evaluated by clinical means after six to eight months. When presence of myocardial
ischemia was suspected, coronary angiography was performed to conﬁrm the suspected diagnosis of ISR.
Clinical ISR was present in total in 34 patients (8.8%). IL-33 was detectable in 185 patients and was below
detection limit in 202 patients. In patients with decreased IL-33 (n = 95), unchanged or non-detectable
levels (n = 210) or increased levels of IL-33 after PCI (n = 82), ISR-rate was 2.1%, 9.5% and 14.6%, respec-
tively (p < 0.05). Accordingly, patients with ISR showed a signiﬁcant increase of IL-33 upon PCI (p < 0.05).
This association was independent from clinical presentation and risk factors as well as numbers and type
of stents. In patients with both stable and unstable coronary artery disease, an increase of IL-33 serum
levels after stent implantation is associated with a higher rate of in-stent restenosis.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
Restenosis after percutaneous coronary intervention (PCI) re-
mains an unsolved clinical problem and certain patients appear
to be at increased risk of developing restenotic complications.
Deﬁning the subgroups of patients at increased or decreased risk
for in-stent restenosis (ISR) would be of massive utility for patient
risk stratiﬁcation and for the understanding of underlying molecu-
lar and cellular mechanisms [1,2].
Restenosis is a multifaceted disease and pathophysiological
mechanisms involved are thought to comprise inﬂammation, pro-
liferation and extracellular matrix remodeling. Inﬂammation
seems to play a central role in the pathogenesis of ISR [1,3,4]. Both
‘‘classical’’ inﬂammation, mediated by neutrophils, monocytes and
T helper type 1 (Th1) lymphocytes, and ‘‘allergic’’ inﬂammation,mainly mediated by eosinophils and T helper type 2 (Th2) lympho-
cytes, are implicated in restenotic reactions [2].
Different inﬂammatory markers for restenosis have been iden-
tiﬁed and include complement components C5a and C3a [5], tumor
necrosis factor (TNF)-a [6] and interleukin (IL)-3 [7]. Circulating
levels of matrix metalloproteinase (MMP)-2, MMP-9, plasminogen
activator inhibitor (PAI)-1 and soluble Fas and Fas ligand were also
shown as a predictive marker for ISR by our group and others
[8–12].
IL-33 is the most recently described member of the IL-1 family
of cytokines and is a ligand for the ST2 receptor [13]. IL-33 is ex-
pressed intracellularly predominantly by stromal cells such as
endothelial and epithelial cells as well as smooth muscle cells
and ﬁbroblasts [14–16]. IL-33 is believed to be released during
necrosis but kept intracellular during apoptosis where it is inacti-
vated by caspases [17,18]. Therefore, IL-33 is recognized as a dual
function cytokine that acts either intracellular to regulate gene
transcription or extracellular via binding to ST2. Upon release,
IL-33 was shown to be recognized by different immune and non-
immune ST2-expressing cells. In such a way IL-33 integrates both
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eosinophils, basophils, mast cells, innate lymphoid cells, and Th2
lymphocytes [16,19]. Thus, IL-33 might function as an alarmin, a
danger signal belonging to the larger family of damage-associated
molecular pattern (DAMP) molecules [15,20].
IL-33 is involved in the pathogenesis of different inﬂammatory
and allergic disorders such as rheumatoid arthritis, asthma, psori-
asis and ulcerative colitis [21–23]. A precise role of IL-33 in the
pathogenesis of cardiovascular diseases is still not well deﬁned.
Dhillon et al. measured IL-33 levels in patients with myocardial
infarction and found that elevated IL-33 was associated with in-
creased mortality in ST-elevation myocardial infarction (STEMI)
[24], but was not related to adverse events in non–ST-elevation
myocardial infarction (NSTEMI) patients [25].
We propose that IL-33 may be an important player in the path-
ogenesis of ISR after stent implantation and therefore circulating
levels of IL-33 could serve as a biomarker for the development of
ISR. The aim of this study was to test whether an increase of IL-
33 after PCI is associated with an increased rate of ISR.2. Methods
2.1. Study population
Blood samples were taken from 387 consecutive patients
undergoing PCI. From these patients 193 had stable angina, 93
NSTEMI, and 101 STEMI, respectively. The PCIs were performed
according to standard techniques by experienced interventional-
ists only. Exclusion criteria were presence of autoimmune diseases,
chronic infections, hepatic or renal disorders. Aspirin and unfrac-
tionated heparin were administered per standard practice. Clopi-
dogrel therapy was started either on the day before angiography
or immediately after stent implantation with 300 mg. After the
procedure, patients were maintained on aspirin 100 mg indeﬁ-
nitely, and clopidogrel 75 mg according to guidelines of European
Society of Cardiology (ESC). Other medications such as beta-block-
ers and angiotensin-converting-enzyme inhibitors were given as
appropriate. Statin therapy was routinely administered to all pa-
tients according to international guidelines. At inclusion time
new antiplatelet drugs like ticagrelor and prasugrel were not yet
available. After enrollment, patients remained in the hospital for
at least 48 h. Informed consent was obtained from each patient.
The study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reﬂected in a priori approval by the eth-
ics committee of the city of Vienna, Austria.
2.2. Blood samples
Two blood samples were taken directly before PCI (at baseline)
and 24 h after PCI. Blood drawing was performed under fasting
conditions whenever possible (in stable patients and 24 h after
the event in patients with acute events). Venous blood was drawn
from the antecubital vein with minimal tourniquet pressure into
serum separator tubes. Samples were allowed to clot for 30 min
(min) before centrifugation (4 C; 3000 g for 15 min) and stored
at 80 C until use.
2.3. Laboratory measurements
IL-33 was measured with a speciﬁc enzyme-linked immunosor-
bent assay (ELISA; R&D Systems; Minneapolis, MN, USA). The min-
imum detection limit of the assay was 23.4 pg/mL. The sensitivity
of the assay is expressed as minimum detectable dose (MDD) and
mean MDD was 0.5 pg/mL. For calculation of the intra-assay coef-
ﬁcient of variability (CV) three samples of known concentrationwere tested twenty times on one plate and mean ± SD was as-
sessed as 3.2 ± 1.0%. For calculation of the inter-assay CV three
samples of known concentration were tested in twenty separate
assays and mean ± SD was assessed as 5.3 ± 0.5%. Laboratory deter-
minations were performed by investigators that were blinded to
clinical characteristics and patients’ outcome.
2.4. Angiographic deﬁnitions
Maximal lumen stenosis was measured within the stent and
within the 5-mm proximal and distal edges of the stent. All mea-
surements were performed by the same investigator that was
blinded to all laboratory results.
2.5. End points
All patients were reevaluated clinically for recurrent anginal
symptoms after six to eight months. Patients with clinical signs
of restenosis underwent re-angiography. The primary end point
of the study was the need for target lesion revascularization due
to restenosis in the presence of symptoms or objective signs of
ischemia during the follow-up.
2.6. Statistical analysis
Sample size calculation was based on the hypothesis that IL-33
increase is associated with at least a 15% higher restenosis rate as
compared to patients with IL-33 decrease. Sample size calculation
revealed that we would need at least 75 patients per group to de-
tect a difference with a power of 80% and signiﬁcance level (two-
tailed) of 0.05 [26]. As IL-33 was not detectable in approximately
50% of patients we increased the sample size accordingly. Contin-
uous variables are expressed as mean ± SD or as median, interquar-
tile range. Categorical variables are summarized as counts and
percentages and were compared by the chi-square or by Fisher ex-
act test. Continuous variables were compared using Student’s t-test
when normally distributed and byMann–Whitney-U test when not
normally distributed. Spearman correlation was used to determine
the correlation between level of IL-33 and cardiovascular risk fac-
tors. Multivariate analysis was performed with the logistic regres-
sion model in which restenosis was used as dependent variable
and potentially confounding baseline variables were used as inde-
pendent variables. Baseline variables were selected for the model if
they (a) had either a clinically plausible relation with the outcome
or (b) appeared to be imbalanced between patients with and with-
out restenosis indicated by a p-value < 0.20. A value of p < 0.05
(two-tailed) was considered statistically signiﬁcant. All statistical
analyses were performed with the statistical software package
SPSS version 18.0 (SPSS, Inc., Chicago, Illinois).3. Results
3.1. Patient characteristics
BMS were used in 283 and DES were used in 104 patients. Clin-
ical ISR was present in total in 34 patients (8.8%; 7 DES and 27
BMS). Target lesion revascularization was performed in all 34 pa-
tients. Baseline demographic data are shown in Table 1. Patients
with and without restenosis at follow-up showed no signiﬁcant
differences in baseline clinical characteristics and cardiovascular
risk factors. However, patients in the restenosis group tended to
have a higher prevalence of hypertension, family history of CAD,
hyperlipidaemia and peripheral artery occlusive disease (PAOD)
(Table 1). There were no signiﬁcant differences in baseline angio-
graphic characteristics (Table 2).
Table 1
Baseline characteristics of study population.
Total (n = 387) Restenosis (n = 34) No restenosis (n = 353) p-Value
Age (yrs) 64.6 ± 12.7 62.8 ± 10.6 64.8 ± 12.9 0.39
Male sex, N (%) 257 (66.4%) 23 (67.6%) 234 (66.3%) 1.00
Hypertension, N (%) 288 (74.4%) 27 (79.4%) 261 (73.9%) 0.55
Family history of CAD, N (%) 31 (8.0%) 4 (11.8%) 27 (7.6%) 0.34
Smoker, N (%) 113 (29.2%) 9 (26.5%) 104 (29.5%) 0.35
Hyperlipidaemia, N (%) 296 (76.5%) 28 (82.4%) 268 (75.9%) 0.53
BMI, (kg m2) 27.7 ± 4.4 27.2 ± 3.9 27.8 ± 4.5 0.49
Diabetes, N (%) 82 (21.2%) 7 (20.6%) 75 (21.2%) 1.00
PAOD, N (%) 19 (4.9%) 3 (8.8%) 16 (4.5%) 0.23
eGFR (mL/min) 89.9 ± 62.8 88.2 ± 37.3 89.9 ± 65.8 0.88
Characteristics of the total cohort (n = 387) and patients with restenosis (n = 34) and without restenosis (n = 353) according to age, sex, body mass index (BMI), estimated
glomerular ﬁltration rate (eGFR), presence of hypertension, family history of coronary artery disease (CAD), hyperlipidaemia, diabetes, peripheral arterial occlusive disease
(PAOD), and smoking status.
Table 2
Angiographic and interventional characteristics of study population.
Total (n = 387) Restenosis (n = 34) No restenosis (n = 353) p-Value
Clinical presentation, N (%) 0.22
Stable CAD 193 (49.9%) 18 (52.9%) 175 (49.6%)
NSTEMI 93 (24.0%) 11 (32.4%) 82 (23.2%)
STEMI 101 (26.1%) 5 (14.7%) 96 (27.2%)
Target vessel, N (%) 0.45
LAD 159 (41.2%) 13 (38.2%) 146 (41.5%)
LCx 91 (23.6%) 8 (23.5%) 83 (23.6%)
RCA 129 (33.4%) 11 (32.4%) 118 (33.5%)
Vein graft 7 (1.8%) 2 (5.9%) 5 (1.4%)
Vessel disease, N (%) 0.36
1-VD 202 (52.2%) 18 (52.9%) 184 (52.1%)
2-VD 108 (27.9%) 7 (20.5%) 101 (28.6%)
3-VD 77 (19.9%) 9 (26.5%) 68 (19.2%)
Number of stents 1.4 ± 0.6 1.4 ± 0.7 1.4 ± 0.6 0.51
Percent stenosis 86.4 ± 10.7 84.6 ± 13.7 86.6 ± 10.4 0.41
Type of stent, N (%) 0.26
BMS 283 (73.1%) 27 (79.4%) 256 (72.5%)
DES 104 (26.9%) 7 (20.6%) 97 (27.5%)
Characteristics of the total cohort (n = 387) and patients with restenosis (n = 34) and without restenosis (n = 353) according to clinical presentation, target vessel, number of
diseased vessel, number and type of stents, and percent of stenosis. CAD denotes coronary artery disease, NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation
myocardial infarction, LAD left anterior descending artery, LCx left circumﬂex artery, RCA right coronary artery, VD vessel disease, BMS bare metal stent, DES drug eluting
stent.
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Fig. 1. Restenosis rate according to the change of IL-33 serum levels. IL-33 serum
levels were measured in the patients before and 24 h after PCI by ELISA as described
under ‘‘Section 2’’. In patients with decreased IL-33, unchanged or non-detectable
(n.d.) levels or increased levels of IL-33 after PCI, in-stent restenosis (ISR) rate was
2.1%, 9.5% and 14.6%, respectively.
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IL-33 was detectable in 185 patients (ranged from 0.4 to
2180.0 pg/mL) and was below detection limit in 202 patients. Med-
ian IL-33 levels before (p = 0.40) or after (p = 0.60) PCI were not dif-
ferent in patients with stable CAD, NSTEMI or STEMI. IL-33 levels at
baseline were associated with age (r = 0.11, p < 0.05) and corre-
lated inversely with estimated glomerular ﬁltration rate (eGFR,
r = 0.10, p < 0.05). Baseline IL-33 was signiﬁcantly higher in fe-
males (p < 0.05) and non-smokers (p < 0.005). Interestingly, IL-33
levels before PCI statistically signiﬁcantly correlated (p < 0.05) with
percent stenosis of the culprit lesion. However, this correlation was
only weak (r = 0.123).
3.3. Decreased IL-33 serum levels after coronary stent implantation
are associated with lower rate of ISR
In patients with decreased IL-33 (n = 95), unchanged or non-
detectable (n.d.) levels (n = 210) or increased levels of IL-33 after
PCI (n = 82), the respective ISR-rate was 2.1%, 9.5% and 14.6%
(p < 0.05) (Fig. 1). IL-33 serum levels before or after PCI were not
associated with ISR at follow-up (p = 0.901 and p = 0.790,
respectively).3.4. Change in IL-33 serum levels in patients with and without
restenosis
Accordingly, patients with ISR showed a signiﬁcant increase of
IL-33 upon PCI (p < 0.05) in the entire cohort (Fig. 2A) as well as
in the patients with acute coronary syndrome (ACS; Fig. 2B) or
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Fig. 2. Change in IL-33 levels according to the presence of ISR. IL-33 serum levels
were measured in the patients before and 24 h after PCI by ELISA as described under
‘‘Section 2’’. Changes in IL-33 serum levels are shown in accordance with presence
(Yes) or absence (No) of in-stent restenosis (ISR) in the entire cohort (panel A) or
patients with acute coronary syndrome (ACS; panel B) or stable coronary artery
disease (CAD, panel C).
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presentation and risk factors as well as numbers and type of stents
as assessed by a multivariate regression model (Table 3).
4. Discussion
In the present study we found that a decrease of IL-33 serum
levels after stent implantation is associated with a lower rate ofTable 3
Logistic regression model assessing the risk of restenosis after stent implantation.
Odds ratio
Univariate
IL-33 decrease 1.0
IL-33 constant, n.d. 4.90
IL-33 increase 7.97
Adjusted for clinical characteristics (age, diabetes, smoking, hypertension)
IL-33 decrease 1.0
IL-33 constant, n.d. 4.91
IL-33 increase 8.19
Adjusted for angiographic and interventional characteristics (presence of ACS, number of
IL-33 decrease 1.0
IL-33 constant, n.d. 4.69
IL-33 increase 7.78
Multivariate analysis was performed with the logistic regression model in which rest
smoking, hypertension) or angiographic and interventional characteristics (presence of
were used as independent variables. n.d. denotes not detectable.in-stent restenosis after PCI in patients with both stable and unsta-
ble CAD. Consequently, patients with ISR showed a signiﬁcant in-
crease of IL-33 upon PCI. Interestingly, levels of IL-33 before PCI
correlated positively with grade of stenosis in target vessel at base-
line, although this correlation was only weak. Multiple logistic
regression demonstrated that changes in IL-33 levels indepen-
dently predicted the occurrence of restenosis after PCI.
Our report is the ﬁrst that showed the predictive value of
changes in IL-33 serum levels for in-stent restenosis after vascular
intervention. The activation status of the inﬂammatory system has
been suggested to play an important role in predicting restenosis
[1,2,4]. Previously, different inﬂammatory markers for restenosis
have been identiﬁed by our group and others including comple-
ment components C3a and C5a [5] and cytokines TNF-a [6], IL-3
[7], IL-6 [27], and IL-10 [28]. Moreover, ISR after stent implantation
was shown to be related to the levels of circulating MMP-2, MMP-
9, PAI-1 and soluble Fas and Fas ligand [8–12].
IL-33 is a recently described member of the IL-1 family of cyto-
kines, which also includes IL-1a, IL-1b and IL-18 [13]. IL-33 is pre-
dominantly expressed by stromal cells such as endothelial,
epithelial and smooth muscle cells [14,21]. Cell damage can induce
necrosis and release of IL-33 [21]. IL-33 was shown to be released
by endothelial cells after damage or injury [17]. We showed re-
cently that nuclear IL-33 is released from necrotic human coronary
artery smooth muscle cells, human adult cardiac myocytes and
cardiac ﬁbroblasts in vitro [14].
Upon release, IL-33 was shown to be recognized by different
immune cells such as Th2 cells, mast cells, basophils, eosinophils,
and to activate these cells [22]. Generally, IL-33 is predominantly
associated with the Th2-related immune response [13]. However,
IL-33 is also able to enhance the production of the Th1 cytokine
interferon-c (IFN-c) by natural killer cells and invariant natural
killer T cells [29]. ST2L, the transmembrane receptor for IL-33, is
also expressed on macrophages, and IL-33 was shown to enhance
lipopolysaccharide-induced TNF-a, IL-6 and IL-1b production from
macrophages [30]. Moreover, IL-33 enhances adhesion and sur-
vival of mast cells, eosinophils and basophils, as well as the release
of different cytokines from these cells [21,22]. In this respect, it is
of interest that eosinophilic inﬁltration was found in case of in-
stent restenosis, and eosinophils have been identiﬁed as important
modulators of restenosis after stent implantation [31,32]. Recent
ﬁndings have also implicated mast cells in the pathogenesis of car-
diovascular disorders [33]. Therefore, it is possible to hypothesize
that IL-33, released by stromal cells such as endothelial and
smooth muscle cells during damage or injury, via activation of dif-
ferent immune cells might play an important role in the process of
restenosis. It should be emphasized, that IL-33 is considered to be a95% Conﬁdence interval p-Value
– –
1.12–21.39 0.035
1.73–36.77 0.008
– –
1.12–21.49 0.035
1.77–37.93 0.007
stents, type of stents, percent stenosis)
– –
1.06–20.67 0.041
1.65–36.57 0.009
enosis was used as dependent variable and clinical characteristics (age, diabetes,
acute coronary syndrome (ACS), number of stents, type of stents, percent stenosis)
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after cellular injury [20].
The paradigm of coronary stenting, leading to vascular injury
and resulting in an inﬂammatory response, and subsequent in-
stent restenosis shares many similar features of the inﬂammatory
cascade that propagates atherosclerosis [34]. Experimental studies
suggest a possible implication of IL-33 in development and pro-
gression of atherosclerosis. IL-33 and its receptor ST2 are expressed
in murine and human atherosclerotic lesions [35,36]. Although
injection of IL-33 into apolipoprotein E (ApoE) knockout mice with
ongoing atherosclerosis reduced atherosclerotic lesions in thoracic
aorta [35], treatment of human endothelial cells with IL-33 in-
creased the expression of adhesion molecules and production of
the chemokine monocyte chemoattractant protein (MCP)-1 and
promoted adhesion of leukocytes to endothelial cells [36], all of
which are features of endothelial activation and are recognized
as an early step in the development of atherosclerosis [34].
Activation of leukocytes is seen as an essential step also in the
development of restenosis after PCI [4].
The association between IL-33 and ISR might be explained by
the direct proinﬂammatory effects of IL-33 on endothelial cells.
Additional to the upregulation of intercellular adhesion mole-
cule-1, vascular cell adhesion molecule-1, and endothelial selectin,
IL-33 also induces IL-6, IL-8, and MCP-1 in endothelial cells [36,37].
Furthermore, IL-33 was shown to induce the activation of nuclear
factor-jB (NF-jB), a transcription factor regulating cytokine syn-
thesis and inﬂammatory activation, in human endothelial cells,
mast cells, eosinophils, and basophils [16,36].
Angiogenesis is recognized as an important factor in the devel-
opment and progression of restenosis. Restenotic lesions develop
intimal neovascularization, apparently necessary for neointimal
growth [38]. Recently, it was also demonstrated that IL-33 induces
vascular permeability and angiogenesis in human endothelial cells
[39].
There are no data available on possible effects of IL-33 on
smooth muscle cells migration and proliferation. However, as hu-
man coronary artery smooth muscle cells express only minor
amounts of the receptor for IL-33, ST2L, as compared to endothelial
cells [14,35], it could be hypothesized that IL-33 has only minor di-
rect effects on the biology of smooth muscle cells, and impacts on
the pathophysiology of the vasculature mostly via its effects on
endothelial cells and immune hematopoietic cells.
Binding of extracellular IL-33 to the heterodimeric receptor
complex consisting of transmembrane ST2L and IL-1 receptor
accessory protein induces recruitment of Myd88 and activation
of NF-jB and mitogen-activated protein kinases [13,21]. Interest-
ingly, a recent study showed that inhibition of MyD88 or IL-1
receptor signalling reduces neointima formation in response to
vascular injury in mice [40].
Although increased levels of the soluble receptor for IL-33, sST2,
is a marker of poor prognosis in patients with heart failure and
myocardial infarction [21], the prognostic value of circulating IL-
33 in cardiovascular disease was not studied extensively. Recently,
Dhillon et al. measured IL-33 levels in 577 patients with NSTEMI
and found no relation of IL-33 levels to adverse events such as
all-cause mortality, heart failure hospitalization, and reinfarction
[25]. However, the same group found that in STEMI patients ele-
vated IL-33 was associated with increased 30-days and 1-year
mortality [24]. Moreover, circulating IL-33 levels were shown to
be increased in patients with different immune-inﬂammatory dis-
eases such as rheumatoid disorders [23,41], systemic sclerosis [42],
and ulcerative colitis [43].
Some limitations of the present study have to be acknowledged.
As the primary endpoint of this study was need for target lesion
revascularization due to restenosis in the presence of symptoms
or objective signs of ischemia during the follow-up we can notexclude that routine follow-up angiography would have revealed
additional cases of ISR. In addition, despite inclusion of 387 pa-
tients only 34 patients (8.8%) developed clinical signs of ISR. There-
fore, larger studies are needed to conﬁrm our results in additional
patient cohorts before any clinical conclusions can be drawn. In
addition, we included patients with DES and BMS. However, mul-
tivariate analysis revealed that the association between IL-33 and
the development of ISR is independent of stent type. Further, our
study is necessarily of an observational nature. Accordingly, our re-
sults may be explained by unmeasured confounding factors. There-
fore, we tried to control for baseline imbalances by multivariate
modeling. However, the possibility of residual or undetected con-
founding is small but cannot be ruled out completely. In addition,
IL-33 was not detectable in 202 patients before or after the inter-
vention. Similar to our ﬁndings, Dhillon et al. found that in more
than half of the patients IL-33 levels were below the lower detec-
tion limit of the assay used [24,25]. Interestingly, the patients with
IL-33 below the detection limit of the assay, showed an intermedi-
ate ISR rate, suggesting that these low levels of IL-33, have no or
only little impact on the development of ISR.
5. Conclusions
In conclusion, we provide evidence that IL-33 might be involved
in the pathogenesis of yet another inﬂammatory pathology,
namely in-stent restenosis after coronary stent implantation [1].
A recent review emphasized the growing importance of inﬂamma-
tory biomarkers that allow identiﬁcation of individuals at high risk
to develop ISR after coronary intervention and stent implantation
for the management of these patients [2]. Based on our ﬁndings
that an increase in IL-33 levels after coronary stent placement is
associated with ISR, we propose here IL-33 as a new circulating
biomarker and a tool to identify patients with an increased risk
of developing in-stent restenosis.
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